Parechovirus infection in human brain organoids: host innate inflammatory response and not neuro-infectivity correlates to neurologic disease

Picornaviruses are a leading cause of central nervous system (CNS) infections. While genotypes such as parechovirus A3 (PeV-A3) and echovirus 11 (E11) can elicit severe neurological disease, the highly prevalent PeV-A1 is not associated with CNS disease. Here, we expand our current understanding of these differences in PeV-A CNS disease using human brain organoids and clinical isolates of the two PeV-A genotypes. Our data indicate that PeV-A1 and A3 specific differences in neurological disease are not due to infectivity of CNS cells as both viruses productively infect brain organoids with a similar cell tropism. Proteomic analysis shows that PeV-A infection significantly alters the host cell metabolism. The inflammatory response following PeV-A3 (and E11 infection) is significantly more potent than that upon PeV-A1 infection. Collectively, our findings align with clinical observations and suggest a role for neuroinflammation, rather than viral replication, in PeV-A3 (and E11) infection.


Statistics
For all statistical analyses, confirm that the following items are present in in the figure legend, table legend, main text, or or Methods section.

n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as as a discrete number and unit of of measurement A statement on on whether measurements were taken from distinct samples or or whether the same sample was measured repeatedly The statistical test(s) used AND whether they are one-or or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.

A description of of all covariates tested
A description of of any assumptions or or corrections, such as as tests of of normality and adjustment for multiple comparisons A full description of of the statistical parameters including central tendency (e.g.means) or or other basic estimates (e.g.regression coefficient) AND variation (e.g. standard deviation) or or associated estimates of of uncertainty (e.g.confidence intervals) For null hypothesis testing, the test statistic (e.g.F, t, r) with confidence intervals, effect sizes, degrees of of freedom and P value noted Give P values as exact values whenever suitable.
For Bayesian analysis, information on on the choice of of priors and Markov chain Monte Carlo settings For hierarchical and complex designs, identification of of the appropriate level for tests and full reporting of of outcomes Estimates of of effect sizes (e.g.Cohen's d, Pearson's r), ), indicating how they were calculated Our web collection on statistics for biologists contains articles on many of the points above.

Data analysis
For manuscripts utilizing custom algorithms or or software that are central to to the research but not yet described in in published literature, software must be be made available to to editors and reviewers.We We strongly encourage code deposition in in a community repository (e.g.GitHub).See the Nature Portfolio guidelines for submitting code & software for further information.

Data Policy information about availability of of data
All manuscripts must include a data availability statement This statement should provide the following information, where applicable: -Accession codes, unique identifiers, or or web links for publicly available datasets -A description of of any restrictions on on data availability -For clinical datasets or or third party data, please ensure that the statement adheres to to our policy The raw data supporting the conclusions of of this article is uploaded in in figshare.comand will be be public once the manuscript is is published.Sequencing results will be be available on on GenBank (accession numbers BankIt: E11 OR886062 and PeV-A OR886056-OR886061).The mass spectrometry proteomics data have been deposited The primary antibodies were validated in our lab using positive control samples.In the experimental analysis of ICC samples a negative control lacking primary antibodies was taken along to control for the non-specific antibody binding to the sample.The dilution used was based on recommendations on manufactures websites and previously used dilutions by fellow scientist reported on Citeab.